Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / NAFDAC clears Deleject needles after...
Regulatory regulatory clarification

NAFDAC clears Deleject needles after alert retraction

Analysis based on 8 articles · First reported Aug 14, 2026 · Last updated Aug 14, 2026

Sentiment
10
Attention
1
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The retraction and safety clearance mitigate potential reputational and financial damage to HMA and the Deleject brand, reassuring distributors and healthcare providers. The event is unlikely to have significant market-wide impact, but it may influence regulatory oversight and supply chain practices in Nigeria's pharmaceutical distribution.

Pharmaceutical Medical Devices
Event Summary

The United States — Food and Drug Administration (NAFDAC) retracted Public Alert No. 042/2026 concerning Deleject Disposable Needles Batch No. 240605, which had reported whitish particulate matter. The agency stated the alert was uploaded in error. Following an investigation triggered by a complaint from pharmacist Jiyah Dadi, NAFDAC traced the product through the distribution chain to manufacturer HMA. The investigation found no non-conformity with Good Manufacturing Practice (GMP) and no manufacturing defect, attributing the issue to a possible supply chain challenge. NAFDAC conducted nationwide surveillance, finding the incident isolated to Kaduna. Affected products were withdrawn as a precaution. NAFDAC reassured the public of product safety and announced plans to strengthen its track-and-trace system.

Key Actions
80 United States — Food and Drug Administration retracted alert
70 United States — Food and Drug Administration investigated complaint HMA
60 United States — Food and Drug Administration failed to share
50 United States — Food and Drug Administration conducted nationwide surveillance
40 United States — Food and Drug Administration strengthening track-and-trace system
Entities Involved
govactor
United States — Food and Drug Administration
NAFDAC is the central regulator; it retracted the alert, conducted the investigation, and reaffirmed product safety, reinforcing its role in ensuring drug quality.
Importance 100.0 Sentiment 10.0
priv
HMA
HMA, the manufacturer, was cleared of any GMP non-conformity, avoiding potential sanctions and reputational damage; the incident highlights supply chain risks.
Importance 80.0 Sentiment 20.0
per
Bitrus Fraden
As NAFDAC's Director of Post-Marketing Surveillance, Fraden led the investigation and public clarification, reinforcing regulatory credibility.
Importance 60.0 Sentiment 10.0
cnt
Nigeria
The event affects Nigeria's pharmaceutical regulatory environment and public health confidence; NAFDAC's actions aim to ensure product safety.
Importance 40.0 Sentiment 10.0
per
Jiyah Dadi
The pharmacist who lodged the complaint; his report triggered the investigation, but no wrongdoing was found on his part.
Importance 30.0 Sentiment 0.0
priv
Zagbayi Pharmacy
The pharmacy that sold the affected product; no sanctions were imposed, but the incident underscores distribution chain responsibilities.
Importance 20.0 Sentiment 0.0
Relationships
United States — Food and Drug Administration related ↔ Nigeria
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.